facebook

Avestha Growth

Scheme Rating

IME Scheme Rating

3 of 5 stars

Can be considered for investments: A combination of an experienced investments professional with reasonable performance, indicates that Avestha Growth can be considered for investments.

IME Strategy Rating

3 of 5 stars

Concentrated Mid and Small Cap Strategy: Concentrated Portfolio (12-18 holdings). Buy-&-Hold Strategy that allows ample room for recognition of our preferred equity characteristics. Sector Agnostic as stock selection approach will be bottom-up. It finds principal basis in Balance sheet strength, Promoter history, Capital efficiency and Business Scalability/Growth runway.

PMS Scheme Ratings are driven by IME’s Proprietary Scheme Rating Methodology, which takes into account our ratings of the Scheme’s investment strategy, its maturity, the investment team, and our separate rating on the AMC that runs this particular scheme. Our views on each of these individual criteria are available via the IME RMS – which you can view by reaching out to one of our relationship managers (using either the live chat or book appointment feature on this site).

IME View on Avestha Growth

Type: Flexi Cap | GARP | AUM (1191.8 cr) | Inc Date (1 Nov 2017)

Avestha Growth- Investment Strategy

Focus on quality stocks to 'capitalise on asymmetric risk-reward'

Avestha Growth Fund is a multi-cap fund with its focus on quality stocks to “capitalise on asymmetric risk-reward”.

Avestha Growth fund aims to construct a concentrated portfolio of 12-18 holdings with a bottom-up approach of stock selection investing across sectors. The fund also follows a buy-and-hold strategy that allows the fund to have ample room for the recognition of its preferred equity characteristics like B/S strength, promoter history, capital efficiency and business scalability.

Trailing Performance

1yr 3yr 5yr Since Inception
Avestha Growth 37.6 27.1 29.1 20.3
S&P BSE 500 TRI 41.1 18.4 22.4 16.5
Alpha over Broad Mkt BM -3.5 8.7 6.7 3.8
Nifty Midcap 150 47.4 25.2 30.4
Alpha over Category BM -9.8 1.9 -1.3

Performance as of: 30-Sep-24 | Inception Date: 01-Nov-17

Fund Managers

Farokh Pandole | 4-star rated FM

Founder & Portfolio Manager

Past Experience: Equity Portfolio Manager (HDFC Life), Head of Indian Equity Distribution (Citigroup Global Markets), VP (Alliance Capital Mutual Fund)

Farokh Pandole’s experience includes sell-side and equity sales roles for 13 years. His experience in Private Equity and Asian coverage at Alliance-DLJ before managing an equity portfolio at HDFC Life gives him a holistic view of his investments.

Fee Structure

Fee StructureFee
Fixed Fee Structure1
Variable Fee Structures0% fixed + 5% no hurdle
Exit Fees

AMC

AMC: Avestha PMS (click link for detailed AMC review)

Not a top recommendation as it is still a young AMC at this time : While there are positives to Avestha PMS (a seasoned core investment team, long-term investment approach), we would rather wait for the PMS to mature prior to recommending it as an investment option. This is primarily driven by factors such as the team's core experience being different from that of running concentrated mandates, the short-age of the PMS strategies, a lack of publicly disclosed portfolios and a high initial ticket size (2cr+) for a PMS that is still to establish its longer-term credentials.

AMC Rating

3 of 5 stars

AMC Pedigree

3 of 5 stars

AMC Size

3 of 5 stars

Team Pedigree

3 of 5 stars

Inv Philosophy

3 of 5 stars

Performance

3 of 5 stars

Free 30-Day Trial of the IME RMS

Details shared above, are only a short-snapshot of the more detailed analysis that resides in IME’s Proprietary RMS (Research Management Solution).

The IME RMS is the first tool ever, to give investors direct access to the insights of the central research team. Investors gain direct access to our ratings, rating rationales & analysis across thousands of funds (MFs, PMSs, AIFs, Global funds), asset classes, categories & more.

 Learn More

IME RMS Demo

Register 30-Day Trial

Note: PMS AMC & Scheme Reviews and Ratings are based on IME Capital’s Proprietary Review and Rating Methodology (read more here: AMC Rating & Scheme Ratings). These reflect the unbiased views of our central research team, based on our assessment of the investment value of these PMS/AIF strategies for our investors. We follow a highly stringent rating-criteria, where approximately 50% of PMS AMC’s & strategies would be rated 2-star or below (this is not meant to indicate that these funds are not investment-worthy, but that they do not currently fulfill the requirements we focus on for recommending funds to our investors — based on our internal views on the merit of the AMC/strategy relative to peers). Reviews & Ratings are primarily based on research of publicly available information (SEBI disclosures, PMS websites, PMS-aggregation platforms, webinar recording, media interviews etc.) and no explicit consent is required from AMCs for the same. While we endeavour to do further due-diligence via direct interactions with the investment teams of AMCs, this is typically restricted to AMC’s that meet our foundational fund selection criteria (reviews on lower-rated AMCs are often based solely on publicly available information). The views reflected in our Reviews & Ratings, are our independent views and may not be shared by the AMC’s and the investment teams. Please read detailed disclaimer for more.

CONNECT WITH US

Use our Live Chat
Book 15-min Introductory Call
WhatsApp us @ +91 96320 07774

IME Capital Pvt. Ltd. is a research-first investments firm. We aim to disrupt the wealth management industry, by shrinking the gap in investment insights between central research teams & RMs/Clients. 

Products
Solutions
Disclaimer MF/PMS/AIF/Direct Equities are all subject to market risks. Please read the scheme information and other related documents carefully prior to investing. Past performance is not indicative of future returns. Please consider your specific investment requirements before choosing a fund or designing a portfolio that suits your needs. Market & other data on this site has been sourced from what are considered to be reliable sources. All views shared (product ratings, views on individual securities etc.) are the proprietary property of IME Capital and cannot be used in any form without explicit written consent. IME Capital Pvt. Ltd. makes no warranties or representations, express or implied, on products offered through the platform (and that of our partners) or on the correctness of data & views shared. It accepts no liability for any damages or losses, however caused, in connection with the use of, or on the reliance of its product or related services. Detailed Disclaimer © 2021 All rights reserved | ARN No: ARN-182445